Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics their estimated earnings by 15.38%, reporting an EPS of $-0.3 versus an estimate of $-0.26, which surprised analysts.
Revenue was up $10,000 from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.0, which was followed by a 3.48% increase in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
| Quarter | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.24 | -0.25 | -0.23 | -0.25 |
| EPS Actual | -0.24 | -0.24 | -0.24 | -0.24 |
| Revenue Estimate | 1.36M | 1.83M | 1.98M | 870.00K |
| Revenue Actual | 3.10M | 434.00K | 1.50M | 1.19M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
